Landscape of short‐acting beta‐agonists ( SABA ) overuse in Europe
Clinical & Experimental Allergy · 2023-02 · 53 (2) · 132-144
DOI: 10.1111/cea.14250 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 05.12.2022. Verfasst von Leticia de Las Vecillas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
This review article provides an overview of short‐acting beta‐agonist (SABA) use and prescribing trends in Europe, summarizing updated data on the results from the industry‐funded SABINA program (SABA use IN asthma) and other studies on this matter. SABA use continues to increase worldwide. Overuse has been defined as ≥3 canisters/year. Almost a third of European patients with asthma, at all severity levels, overuse SABA. Guidelines recommend close monitoring of patients who overuse SABA and avoiding over‐reliance on SABA monotherapy. SABA overuse is associated with increased risk of asthma exacerbations and mortality, increased use of health services and negative physical and mental health outcomes. Reliance on SABA monotherapy can be unsafe and therefore it is necessary to change asthma treatment approaches and policies. Changes in physician and patient behaviours towards SABA use are required to ensure that patients with asthma are not over‐reliant on SABA monotherapy. Notwithstanding, the limitations of the studies on the use of SABA should be considered, taking into account that the prescription/purchase of medication canisters does not always represent the actual use of the medication and that associations between SABA overuse and poor asthma outcomes may not be directly causal. National health systems and asthma guidelines must align asthma management with global recommendations and adjust them to local needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain.
ORCID-Profile: Leticia de Las Vecillas, Santiago Quirce
Zitieren
APA
de Las Vecillas, L., & Quirce, S. (2023). Landscape of short‐acting beta‐agonists ( SABA ) overuse in Europe. Clinical & Experimental Allergy, 53(2), 132-144. https://doi.org/10.1111/cea.14250
Vancouver
de Las Vecillas L, Quirce S. Landscape of short‐acting beta‐agonists ( SABA ) overuse in Europe. Clinical & Experimental Allergy. 2023;53(2):132-144. doi:10.1111/cea.14250
BibTeX
@article{deLasVecillas2023,
author = {de Las Vecillas, Leticia and Quirce, Santiago},
title = {Landscape of short‐acting beta‐agonists ( SABA ) overuse in Europe},
journal = {Clinical & Experimental Allergy},
year = {2023},
volume = {53},
number = {2},
pages = {132--144},
doi = {10.1111/cea.14250}
}
EUVIMED